# EW — Edwards Lifesciences · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** EW  
**Sources:** 21  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-ew-edwards-lifesciences-catalysts-narrative-risks-5910

---

# Edwards Lifesciences (EW) — Research Snapshot

*All figures below are point-in-time data points from the cited sources, not investment advice.*

## Current Snapshot (as of Oct 2–3, 2026)
EW trades at roughly **$85** (sources cite $85.15–$85.28), with a market cap of ~**$49.05–$49.1B**, below its 50-day SMA ($88.48) but above its 200-day SMA ($85.13), and inside a 52-week range of $72.30–$96.29 [[10]](https://tickernerd.com/stock/ew-forecast/)[[12]](https://clearank.com/stock/ew-stock-analysis/)[[16]](https://tickflow.io/stock/EW/forecast). It remains an S&P 500 member in the Healthcare/Medical Devices sector [[1]](https://www.ad-hoc-news.de/boerse/news/corporate-news/edwards-lifesciences-stock-steadies-as-investors-await-fresh-catalysts/70061038)[[10]](https://tickernerd.com/stock/ew-forecast/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-ew-edwards-lifesciences-catalysts-narrative-risks-5910 (free to sign up)._
